Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

Korábbi kezelés

• History of cytotoxic chemotherapy less than or equal to 12 months prior to rectal or breast cancer diagnosis
• Any prior pelvic radiotherapy
• History of GI perforation ≤12 months prior to enrollment
• Receiving any parenteral nutrition or enteral (tube) feeding or using similar nutritional supplement during the study period
• Currently participating in or has participated in a study of an investigational agent or investigational device ≤4 weeks of the first dose of treatment

Más betegség

• Allergic reaction to any of the treatment agents
• Currently active second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ
• History of predisposing colonic or small bowel disorders with severe or rapidly worsening symptoms (not related to current cancer symptoms)
• History of uncontrolled congestive heart failure defined as ew York Heart Association Class (NYHA) Class III or greater
• Known psychiatric or substance abuse disorders that would interfere with adhering to the requirements of the trial

Laborértékek

• Medical condition or laboratory abnormality that could impact participant safety or data validity, in the opinion of the medical investigators.

Egyéb

• Pre-existing grade ≥3 neuropathy
• Pregnant or breastfeeding
• Currently perform overnight shift work more than one day/week on average
• Strictly adhering to a \<10-hour eating window on most days

• Any sex/gender of any ethnic/racial background
• Age greater than or equal to 18 years
• Histologically-confirmed rectal cancer stage II, III, or IV (if curative) or human epidermal growth factor receptor 2-positive (HER2+) or triple negative breast cancer stage I, II, or III (only if definitive intent) per American Joint Committee on Cancer (AJCC) criteria
• BMI 18.5 kg/m2 or greater
• Receiving either neoadjuvant therapy with curative intent (breast cancer patients) or total neoadjuvant therapy with a 5-fluorouracil-based regimen and curative intent (rectal cancer patients)
• Has completed ≤ 4 weeks of neoadjuvant treatment prior to study enrollment
• Willing and able to adhere to the assessments, visit schedules, prohibitions, and restrictions